Drug Profile
Research programme: antibodies therapeutics - Immune-Onc Therapeutics
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Immune-Onc Therapeutics
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 02 Mar 2022 Early research is still ongoing for Cancer in USA
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)